TY - JOUR AB - A 63‑year‑old man was hospitalized for immune check‑point inhibitors (ICIs) medicated pneumonitis, secondary to treatment with pembrolizumab for non‑small cell lung cancer. He was treated with high dose steroids, mycophenolate mofetil, empiric broad spectrum antibiotics and empiric trimethoprim‑sulfamethoxazole and intravenous immunoglobulin. Despite the aforementioned treatment, his condition continued to deteriorate. The patient was admitted to the intensive care unit. While intubated, he underwent bronchoscopy and lavage, which was analyzed for potential infectious agents. Cytomegalovirus (CMV) pneumonia was diagnosed and treated. He passed away despite antiviral treatment and maximal supportive care. CMV infection should be suspected in patients failing to recover from toxicities of ICIs with appropriate immunosuppression. AD - Department of Oncology, Galilee Medical Centre, Nahariya 22100, Israel Department of Radiology, Galilee Medical Centre, Nahariya 22100, Israel AU - Badran,Omar AU - Ouryvaev,Anton AU - Baturov,Veronika AU - Shai,Ayelet DA - 2021/06/01 DO - 10.3892/mco.2021.2282 IS - 6 JO - Mol Clin Oncol KW - non‑small cell lung cancer cytomegalovirus pneumonia immunosuppressive therapy immunotherapy PY - 2021 SN - 2049-9450 2049-9469 SP - 120 ST - Cytomegalovirus pneumonia complicating immune checkpoint inhibitors‑induced pneumonitis: A case report T2 - Molecular and Clinical Oncology TI - Cytomegalovirus pneumonia complicating immune checkpoint inhibitors‑induced pneumonitis: A case report UR - https://doi.org/10.3892/mco.2021.2282 VL - 14 ER -